Prognostic value of 18F-FDG PET-CT in patients with peripheral T-cell lymphoma
10.3760/cma.j.issn.1009-9921.2014.12.007
- VernacularTitle:18F-FDG PET-CT显像在外周T细胞淋巴瘤预后评估中的应用
- Author:
Chongyang DING
;
Tiannyu LI
;
Lei FAN
;
Jin SUN
;
Wenping YANG
;
Wei XU
;
Biao LIU
- Publication Type:Journal Article
- Keywords:
Peripheral T-cell lymphoma;
Positron emission tomography;
18F-fluoro-deoxy-glucose;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2014;23(12):729-732,736
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the prognostic value of interim and post-therapy 18F-FDG PET-CT in patients with peripheral T-cell lymphoma.Methods A retrospective analysis was conducted on data from 44 patients with newly diagnosed peripheral T-cell lymphoma who underwent interim (after 3 cycles of chemotherapy,27 cases) or posttherapy PET-CT (after the completion of first-line therapy,35 cases).Interim and posttherapy PET-CT status (positive vs negative) was visually interpreted according to criteria of the International Harmonization Project,and PET-CT status was assessed for its ability to predict progression-free survival (PFS) and overall survival (OS).Results Interim 18F-FDG PET-CT results were positive in 16 cases and negative in 11 cases.The median PFS and OS in the patients with positive results were 8 months and 14 months,respectively,while those in patients with negative results were 30 months and 39 months,respectively.The 2-year PFS and 3-year OS rates in patients with positive results at interim PET-CT were 18.8 ％ (3/16) and 12.5 ％ (2/16),respectively,while those in patients with negative results were 90.0 ％ (10/11) and 63.6 ％ (7/11),respectively (x2 =13.092,P =0.000; x2 =7.386,P =0.007,respectively).Posttherapy 18F-FDG PET-CT results were positive in 14 cases and negative in 21 cases.The median PFS and OS in patients with positive results were 10 months and 22 months,respectively,while those in patients with negative results were 26 months and 38 months,respectively.The 2-year PFS and 3-year OS rates in patients with positive results at posttherapy PET-CT were 7.1％ (1/14) and 14.3 ％ (2/14),respectively,while those in patients with negative results were 76.2 ％ (16/21) and 57.1％ (12/21),respectively (x2 =15.574,P =0.000;x2 =6.245,P =0.012,respectively).Conclusion Both interim PET-CT status and posttherapy PET-CT status have significant value in monitoring response to therapy and predicting prognosis for patients with peripheral T-cell lymphoma.
